TAPSE/sPAP ratio and RV S' velocity prognostic values could not be determined because the provided text contains only ICMJE publication guidelines and no clinical study data.
Observational
Are echocardiographic markers of right ventricular function (TAPSE/sPAP, RV S', RV S'/sPAP) associated with adverse outcomes in hospitalized COVID-19 patients?
Non-invasive echocardiographic markers of right ventricular function, particularly the RV S'/sPAP ratio, are associated with adverse clinical outcomes and may aid in early risk stratification for hospitalized COVID-19 patients.
Aim: This study aimed to evaluate the association between the tricuspid annular plane systolic excursion (TAPSE) systolic pulmonary artery pressure (sPAP) ratio, right ventricular (RV) S′ velocity, RV S′/sPAP ratio and, adverse clinical outcomes in hospitalized COVID-19 patients.Materials and Methods: A retrospective cohort of 100 adult patients hospitalized with laboratory-confirmed COVID-19 who underwent transthoracic echocardiography (TTE) was analyzed. Patients were classified into two groups according to clinical outcomes: adverse outcome (ICU admission, mechanical ventilation, ARDS, or in-hospital mortality) and favorable outcome. Echocardiographic parameters (TAPSE, sPAP, RV S′, TAPSE/sPAP, and RV S′/sPAP) were compared between groups, and receiver operating characteristic (ROC) curve analysis was performed to assess discriminative performance in this exploratory analysis.Results:Thirty-two patients experienced adverse outcomes. The TAPSE/sPAP ratio (0.44 ± 0.18 vs. 0.55 ± 0.22, p = 0.006), RV S′ velocity (9.17 ± 2.1 cm/s vs. 10.54 ± 2.1 cm/s, p = 0.004), and RV S′/sPAP ratio (0.28 ± 0.10 vs. 0.33 ± 0.08, p = 0.008) were significantly lower in the adverse outcome group. ROC analysis showed fair discriminative performance for TAPSE/sPAP, RV S′, and RV S′/sPAP with AUCs of 0.686, 0.691, and 0.753, respectively.Conclusion:TAPSE/sPAP, RV S′, and RV S′/sPAP are non-invasive echocardiographic markers associated with adverse outcomes in hospitalized COVID-19 patients. Their combined use may contribute to early risk stratification in an exploratory, hypothesis-generating context.
Kunak et al. (Fri,) conducted a observational in COVID-19. TAPSE/sPAP Ratio, RV S′ Velocity, and RV S′/sPAP Ratio was evaluated. TAPSE/sPAP ratio and RV S' velocity prognostic values could not be determined because the provided text contains only ICMJE publication guidelines and no clinical study data.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: